Development of encapsulation materials and design for implantable 3D bioprinted pancreatic cells

可植入 3D 生物打印胰腺细胞的封装材料和设计的开发

• 批准号: 543791-2019
• 负责人: Piret, James
• 金额: $ 1.82万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2019
• 资助国家: 加拿大
• 起止时间: 2019-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=680500
• 关键词: Development; encapsulation; materials; design; implantable

Emerging cellular therapies have the potential to both greatly improve the health of individuals and to reduce healthcare costs with improved treatments for injuries or curing diseases. For example, it has been established that a cellular transplant therapy can reverse and potentially cure type 1 diabetes. However, the development of reliable and economical means of mammalian cell manufacturing and delivery of these therapies is essential to ensure that many promising emerging health care technologies become widely available to the patients who need them. Thus, the great promise of these emerging treatments comes with great challenges, many of those in the field of cell culture process and device engineering that this project addresses. Ultimately, increased access to safe and affordable cell culture products will improve the quality of many thousands of Canadian lives. UBC and Canadian multidisciplinary groups are among the leaders in this area of research. Exporting these technologies and knowledge should benefit populations around the world as well as translate into substantial commercial benefits for Canadians.

新兴的细胞疗法有潜力极大地改善个人健康，并通过改进损伤或治疗疾病的治疗方法来降低医疗成本。例如，已经确定细胞移植疗法可以逆转并有可能治愈 1 型糖尿病。然而，开发可靠且经济的哺乳动物细胞制造和提供这些疗法的方法对于确保许多有前途的新兴医疗保健技术能够广泛提供给需要它们的患者至关重要。因此，这些新兴疗法的巨大前景也伴随着巨大的挑战，其中许多挑战属于该项目所解决的细胞培养过程和设备工程领域。最终，增加获得安全且负担得起的细胞培养产品的机会将改善成千上万加拿大人的生活质量。 UBC 和加拿大多学科小组是该研究领域的领导者。出口这些技术和知识应该造福世界各地的人们，并为加拿大人转化为巨大的商业利益。